Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

24

May 2019

Aequus to supply Kensington Eye Institute with Zepto Capsulotomy system; Extends Distribution Agreement with Mynosys

Aequus Pharmaceuticals Inc is pleased to announce an agreement for the Zepto Precision Pulse Capsulotomy device Zepto with The Kensington Eye Institute a world renowned clinic and leader in Canada for cataract glaucoma and retina surgery Additionally Aequus is pleased to announce the extension of th...

24

May 2019

Trovagene Announces Research Collaboration with Nektar Therapeutics

Trovagene Inc a clinicalstage oncology therapeutics company taking a precision medicine approach to develop drugs that target cell division mitosis for the treatment of leukemias lymphomas and solid tumor cancers announced today that Trovagene and Nektar have entered into a research collaboration to...

23

May 2019

Be The Match BioTherapies® Announces Strategic Collaboration with Kiadis Pharma to Accelerate Patient Access to Haploidentical Stem Cell Therapies

Be The Match BioTherapies an organization offering solutions for companies developing and commercializing cell and gene therapies and Kiadis Pharma NV Kiadis Euronext Amsterdam and Brussels KDS a clinical stage biopharmaceutical company today announced a strategic collaboration to support clinical e...

23

May 2019

Halozyme Announces argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement

Halozyme Therapeutics Inc a biotechnology company developing novel oncology and drugdelivery therapies today announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February

22

May 2019

Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration

Gotham Therapeutics a biotechnology company developing a novel drug class targeting RNAmodifying proteins and ZoBio the leading contract research organization in integrated fragmentbased drug discovery today announced significant progress made as part of their collaboration to identify therapeutic l...

press releasesRead more...

24

May 2019

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

Novocure today announced that the US Food and Drug Administration FDA has approved the NovoTTFL System in combination with pemetrexed plus platinumbased chemotherapy for the firstline treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma MPM NovoTTFL is a noninvasiv...

24

May 2019

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp a clinicalstage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric pain and addiction conditions as well as to improve biodefense announced today that it has inlicensed a Phase asset TNX TRGQ doublemutant cocaine est...

23

May 2019

ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

ProBioGen AG a premier service and technology provider for complex therapeutic antibodies and glycoproteins today announced the closing of a services and license agreement with Abcuro Inc Pursuing a new generation of immune modulatory biotherapeutics Abcuro has developed a new first in class antibod...

23

May 2019

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

Agile Therapeutics Inc a womens healthcare company today announced that the US Food and Drug Administration FDA has accepted for review the Companys New Drug Application NDA resubmission for Twirla AG an investigational lowdose combined hormonal contraceptive patch

23

May 2019

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Therapeutics Inc has engaged Echelon Wealth Partners to determine the value on a riskadjusted basis of its cannabidiol CBD therapeutic products for the prevention and treatment of graft versus host disease GVHD and to assist with the review of potential outlicensing opportunities for the co...

EventsRead more...

23 - 24

May 2019

Hospital Management and Patient Safety 2019

Meetings International Pte Ltd
Las Vegas

28 - 28

May 2019

10th Annual Clinical Trials Summit 2019

Virtue Insight
Kohinoor Continental Hotel

28 - 30

May 2019

8th Annual Biologics Manufacturing Korea 2019

Imapac
Novotel Ambassador Seoul Gangnam

03 - 04

Jun 2019

Pre-Filled Syringes West Coast 2019


Hyatt Regency Mission Bay Spa and Marina

Advertisements

Rousselot - X-PURE®

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    Ligand Decorated Theranostic Nanomedicines

    The drug absorption in cancer cells from the conventional dosage form is limited due to poor dissolution toxic effect and drug resistance along with debilitating adverse effects such as nausea vomiting temporary loss of physical strength and energy neuropathy and finally organ failure

EDITORIAL SECTION